文献速递乳腺癌胸部肿瘤消化系统肿瘤

抗ERBB2抗体药物偶联物诱导间质性肺病综述

Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review.
PubMed 文献 · JAMA Oncol · 2021-01-01

本综述总结了抗ERBB2抗体药物偶联物(ADC)相关肺毒性的发病机制与流行病学特征。虽然尚无专门指南,但基于药物诱导及免疫治疗相关间质性肺病(ILD)的一般原则可推导出诊疗建议:有症状ILD应停用ADC,仅在无症状且完全缓解后可考虑重新引入,糖皮质激素是治疗基石。早期诊断和充分治疗可能改善这类药物的治疗指数。

要点

  • 有症状的ADC相关ILD应停用ADC,仅无症状且完全缓解后可考虑重新引入。
  • 糖皮质激素是ILD治疗基石,剂量应根据事件严重程度调整。
  • 早期诊断和充分治疗ADC诱导的ILD可能改善治疗指数。

核心结论

  • 抗ERBB2 ADC相关ILD虽无专门指南,但可基于药物诱导及免疫治疗相关ILD的一般原则进行诊疗。
  • 早期诊断和更充分的治疗可能改善ADC的治疗指数,支持其跨瘤种安全应用。

研究设计与样本

  • 本文为综述,总结了抗ERBB2 ADC相关肺毒性的发病机制与流行病学特征。

主要发现

  • 临床试验中抗ERBB2 ADC相关ILD死亡已有报告,发生率不一。
  • 有症状ILD应停用ADC,仅无症状且完全缓解后可考虑重新引入。
  • 糖皮质激素是ILD治疗基石,剂量应根据事件严重程度调整。

关键数值与推荐

  • 有症状ILD:停用ADC。
  • 重新引入ADC:仅考虑用于无症状且完全缓解的病例。
  • 糖皮质激素:ILD治疗基石,剂量根据严重程度调整。

临床怎么用

  • 临床医生应接受培训以识别和管理抗ERBB2 ADC相关ILD。
  • 对接受抗ERBB2 ADC治疗的患者,应监测ILD症状并及时处理。

局限性

  • 尚无专门针对ADC相关ILD诊断和管理的指南。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In the past decade, ERBB2 (formerly HER2)-directed antibody-drug conjugates (ADCs) have substantially changed treatment of both advanced and early-stage ERBB2-positive breast cancer. Novel conjugates are now showing activity in trials of other ERBB2-associated tumors, leading to the recent US Food and Drug Administration approval of trastuzumab deruxtecan for ERBB2-positive gastric cancer, as well as beneficial results in colorectal, lung, and bladder cancer. It is thus possible that anti-ERBB2 ADCs may become a treatment option for multiple types of tumors because many have at least some expression of ERBB2. Despite an improved overall therapeutic index, clinical observations have recently raised a concern regarding potential lung toxicity of anti-ERBB2 ADCs. Deaths related to interstitial lung disease (ILD) have been reported with variable incidence in trials testing anti-ERBB2 conjugates, warranting appropriate training of clinicians for the identification and management of this toxic effect. OBSERVATIONS: Although no specific guidelines are available for the diagnosis and management of ADC-related ILD, some recommendations can be derived based on general principles adopted for drug-induced and immunotherapy-related ILD. Overall, in symptomatic ILD, the ADC should be discontinued. Reintroduction of the conjugate can be considered only in asymptomatic cases after complete resolution. Corticosteroids represent the cornerstone of ILD treatment, and dosing should be adapted according to the severity of the event. Additional treatments can be considered based on the clinical scenario. CONCLUSIONS AND RELEVANCE: This review summarizes the current knowledge on the pathogenesis and epidemiologic characteristics of anti-ERBB2 ADC-related lung toxicity, proposing strategies for its diagnosis and treatment. Earlier diagnosis and more adequate treatment of ADC-induced ILD may improve the therapeutic index of this important class of anticancer agents, allowing for a safe expansion of anti-ERBB2 ADCs across tumor types.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Tarantino P, Modi S, Tolaney SM, et al. Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review. JAMA Oncol. 2021. PMID: 34647966. doi:10.1001/jamaoncol.2021.3595

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。